Biomedical subjects

N Scheiermann

Publications and source records attributed to N Scheiermann.

59 records · Page 4Linked to original sources

PubMed1977

[Reactions to inactivated influenza vaccines (alorbat and begrivac s) (author's transl)].

Possible side effects to two commercial influenza vaccines (Alorbat and Begrivac S) were investigated in 893 adults (18-60 years). Both vaccines, administered by jet injections, were similarly tolerated. About 90% of vaccinated subjects had neither subjective nor objective reactions. Swelling or pain at the site of injection was reported by 11.5% of those vaccinated by Alorbat, 4.5% complained of not feeling well but only 1.1% had verifiable disorders. Local reactions occurred in 12.4% of those receiving Begrivac S, with 7.7% systemic reactions of which 1.1% were verifiable. Those re-vaccinated had a similar incidence of side reactions to those with primary vaccinations. Reactions which did occur were obviously due to the vaccination method. One person had urticaria and oedema, possibly due to reaction to foreign protein; this would suggest that the degree of purity of the vaccine should be checked by the manufacturers.

Adolescent↗

PubMed1977

[Permeability of dialysis membranes for hepatitis-B virus: on the prophylaxis of hepatitis in a haemodialysis centre (author's transl)].

Dialysis fluids of two hepatitis-Bs (HBs) antigen-positive dialysis patients were tested for hepatitis-B virus. Total dialysate volume of 5.5 litres each - as obtained on haemodialysis with the Redy-recirculation system - was concentrated by ultrafiltration and trap and rate-zonal ultracentrifugation, followed by fractionation, and purified. Electron-microscopic evidence of permeability of an intact dialysis membrane for hepatitis-B was obtained. Concentration of hepatitis-B virus was at least 10(3) to 10(4) particles per total volume. Because of the potential infectiousness of the dialysis apparatus by effective heat sterilisation after every dialysis is essential.

Adolescent↗

PubMed1977

[Morphological alteration and desintegration of dane particles after exposure with "Gigasept". A first methological attempt for the evaluation of the virucidal efficacy of a chemical disinfectant against hepatitisvirus B ( author's transl)].

A test system based on morphological alterations and desintegration of hepatitis virus B (HBV) is presented for the approximative evaluation of the virucidal efficacy of a chemical disinfectant. Dane particles, supposed to be the infectious entity of HBV, were partially purified by a trap and a rate zonal ultracentrifugation from serum samples of a patient with chronic hepatitis undergoing an immune suppressive treatment because of leukemia. "Gigasept" on the basis of succine dialdehyd and formaldehyd served as disinfectant for this investigation. In one experiment partially purified Dane particles were exposed to the action of a 5% solution of "Gigasept" on electron microscopic grids. Morphological alterations resulting in derounding, break up of the outer membrane, spiral uncoiling as well as asymmetric enlargement of the space between the outer membrane and the core of the HBV was observed after 2 mins. After 15 mins, the HBV were diffusely stained with loss of the characteristic substructure and became polygonal. The decrease of the number of the particles was proportional to the length of the contact time with the disinfectant. In a second series equal volumes of a 5% solution of "Gigasept" and of a HBV containing serum were in contact for 2 hours, with consecutive purification and morphological characterization of the HBV. The sedimentation of the HBs antigenicity differed from the control. A part of the Dane particles was diffusely stained and lost its substructure. Moreover empty particles in the range of the HBc antigen were found. Another part of Dane particles, however, was morphologically unchanged. The relation of intact and non intact particles could possibly serve as parameter for the HBV virucidy.-Thermo inactivation (3 mins, +98 degrees C) of the HBV in a serum was undertaken for comparison.

Aldehydes↗

PubMedDate not supplied

Post-exposure use of human diploid cell culture rabies vaccine.

880 individuals, 120 of which were exposed to rabid animals, were immunized pre- or post-exposure with 2 different BPL-inactivated and concentrated rabies vaccines prepared in HDC strains WI-38 and MRC-5. The vaccines were well tolerated and no major side effects were observed after primary immunization with 3-10 doses or 1 booster vaccination. The dynamics of neutralizing, antibody formation and persistence of antibodies in 4 different groups of vaccinees are described. The groups were vaccinated pre-exposure (I) on days 0, 28 and 56; (II) on days 0, 7 and 14; (III) on days 0, 3, 7 and 21; and (IV) post-exposure on days 0, 3, 7, 14, 30 and 90. High antibody levels--persisting for at least 30 months--were obtained in all patients. The CFT, using a concentrated and purified virion antigen, was highly specific for rabies virus antibody demonstration. Since in some 50 patients under severe risk, after having been bitten and/or scratched by proven rabid animals, not a single breakthough of immunity was observed during an observation time between 1/2 and 3 years, the protective effect of the HDCS-rabies vaccines seems to be excellent. With regard to their high immunogenicity and extremely low reactogenicity, the new HDCS-vaccines can be recommended for prophylactic and post-exposure immunization of man without any reserve. Data on simultaneous application of homologous anti-rabies gammaglobulin from man (20 I.E./kg body-weight) and HDCS-vaccines are also presented and discussed.

Adolescent↗

PubMedDate not supplied

Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.

Anti-neuraminidase antibody (ANAB) formation was determined in serum and nasal washing fluids pre- and post-vaccination in 278 adult healthy volunteers vaccinated with different types of current experimental and conventional influenza vaccines. The best systemic ANAB formation expressed as conversion rate (CR) was observed with the subunit vaccine "Sandovac" (CR = 90%) followed by the split virion vaccine "Begrivac S" (CR = 66%), the whole virion vaccine "Alorbat" (CR = 65%) and the live attenuated vaccine "Alice" (CR = 58%). The best local ANAB formation was obtained with live attenuated vaccines (CR = 47-50%) followed by "Begrivac S" (CR = 34%) and "Alorbat" (CR = 17%). The subunit vaccine, unfortunately, could not be tested for ANAB formation. On the basis of this data the optimal method of immunization against influenza would consist of simultaneous topical and parenteral application of live attenuated and inactivated subunit or split vaccine.

Administration, Intranasal↗